Return to site

A Groundbreaking Global Alliance Forms to Find Effective Response to the Deadliest Human Brain Tumor

GBM AGILE (An Adaptive, Global, Innovative Learning Environment) to Implement Unprecedented International Clinical Trial
This year approximately 12,000 individuals in the US and tens of thousands more around the globe, including 35,000 in China alone, will receive a diagnosis of glioblastoma multiforme (GBM) from their doctors. GBM is the most common adult brain tumor and it is highly aggressive. In fact, fifty percent of GBM patients will survive for a year or less. Five-year survival for GBM is less than two percent – and, unfortunately, these dismal statistics have not changed for decades.